Reuters logo
BRIEF-Nordic Nanovector adapts clinical development plan for Betalutin in Follicular Lymphoma
October 15, 2015 / 5:18 AM / 2 years ago

BRIEF-Nordic Nanovector adapts clinical development plan for Betalutin in Follicular Lymphoma

Oct 15 (Reuters) - Nordic Nanovector ASA :

* Adapts clinical development plan for Betalutin in Follicular Lymphoma

* Aim is to enhance the chances of Betalutin, gaining regulatory approval with a competitive product profile

* Says current cash resources expected to be sufficient until first submission, anticipated in H1 2019

* Revised plan sees previous dose-finding element of pivotal PARADIGME trial being expanded and integrated into Phase 1/2 (Lymrit 37-01) trial

* Says revised phase 1/2 trial is projected to read out around end of Q1 2017

* PARADIGME is now being planned as a single arm efficacy and safety trial

* PARADIGME trial is now expected to start in H1 2017

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below